Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. 1990

H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
Department of Infectious Diseases and Immunology, School of Veterinary Medicine, State University of Utrecht, The Netherlands.

The acyclic purine nucleoside analogue 9-(2-phosphonomethoxyethyl)adenine [PMEA; formerly referred to as 9-(2-phosphonylmethoxyethyl)adenine] is a potent and selective inhibitor of human immunodeficiency virus replication in vitro and of Moloney murine sarcoma virus-induced tumor formation in mice. In the latter system PMEA has stronger antiretroviral potency and selectivity than 3'-azido-3'-thymidine (AZT). We have now investigated the effect of the drug in cats infected with the feline immunodeficiency virus (FIV). In vitro, PMEA was found to efficiently block FIV replication in feline thymocytes (50% effective dose, 0.6 microM). When administered to cats at doses of 20, 5, or 2 mg/kg per day, PMEA caused a dose-dependent suppression of FIV replication and virus-specific antibody production. Seropositive field cats with signs of opportunistic infection (gingivitis, stomatitis, and diarrhea) showed clinical improvement during PMEA therapy (5 mg/kg per day) and recurrence of the disease after treatment was discontinued. Thus, FIV infection in cats is an excellent model to test the efficacy of selective anti-human immunodeficiency virus agents in vivo.

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012190 Retroviridae Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES). Leukemogenic Viruses,Leukoviruses,Oncornaviruses,Oncovirinae,Oncoviruses,Oncoviruses, Type C,RNA Tumor Viruses,Retroviruses,Type C Oncoviruses,C Oncovirus, Type,C Oncoviruses, Type,Leukemogenic Virus,Leukovirus,Oncornavirus,Oncovirus,Oncovirus, Type C,RNA Tumor Virus,Retrovirus,Tumor Virus, RNA,Tumor Viruses, RNA,Type C Oncovirus,Virus, Leukemogenic,Virus, RNA Tumor,Viruses, Leukemogenic,Viruses, RNA Tumor
D012192 Retroviridae Infections Virus diseases caused by the RETROVIRIDAE. Retrovirus Infections,Infections, Retroviridae,Infections, Retrovirus,XMRV Infection,Xenotropic MuLV-related Virus Infection,Xenotropic Murine Leukemia Virus-related Virus Infection,Infection, Retroviridae,Infection, Retrovirus,Infection, XMRV,Infections, XMRV,Retroviridae Infection,Retrovirus Infection,XMRV Infections,Xenotropic MuLV related Virus Infection,Xenotropic Murine Leukemia Virus related Virus Infection

Related Publications

H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
January 1994, Folia biologica,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
November 1992, Biochemical pharmacology,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
February 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
July 1999, European journal of pharmacology,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
July 1991, Antiviral research,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
February 1994, The Journal of infectious diseases,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
December 1992, Veterinary immunology and immunopathology,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
May 1995, The Journal of infectious diseases,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
March 2003, La Revue du praticien,
H Egberink, and M Borst, and H Niphuis, and J Balzarini, and H Neu, and H Schellekens, and E De Clercq, and M Horzinek, and M Koolen
May 1989, Veterinary immunology and immunopathology,
Copied contents to your clipboard!